subslover
2 주 전
Clover Health to Report Third Quarter 2024 Financial Results on November 6
FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health’s third quarter 2024 business and financial results.
Third Quarter 2024 Conference Call and Webcast Details:
What: Clover Health’s Third Quarter 2024 Earnings Conference Call
When: Wednesday, November 6, 2024, at 5:00 p.m. Eastern Time
Dial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for callers outside the U.S.) and enter the conference ID: CLOVQ324
Webcast: A live and archived webcast of the conference call will be accessible from the Investor Relations section of Clover Health’s website at https://investors.cloverhealth.com/ for 12 months
Jimmy Joe
2 주 전
All I will say is this........ "they" go after Keith Gill for posting MEMEs and accuse him of stock manipulation.
Cramer, who has his Mad Money Show gives advice on buys and sells all the time, however, he gets a break because his "show" is considered entertainment.
Yes, he and all his comrades are in lockstep with one another. Does not matter who or on what business channel. It's all connected to the 1% who must make their money. Retail investors, institutions, and pension funds who play by the rules get screwed. IMNSHO
They cannot keep $CLOV down IMO. I still maintain that $CLOV is heavily manipulated. "They" know what the deal is. Do not let them steal your shares~!
HODL
subslover
3 주 전
2025 Clover Health Medicare Advantage Benefits Demonstrate Commitment to New Jersey Seniors
Company’s affordable, benefit-rich flagship PPO plans now have 4 Star rating
FRANKLIN, Tenn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Clover Health (Nasdaq: CLOV) (“Clover” or “the Company”) has announced the debut of its 2025 Medicare Advantage (MA) plan offerings in New Jersey. Clover offers a range of affordable and flexible healthcare options for Medicare beneficiaries, which are designed to meet the unique needs of New Jersey seniors, especially those on fixed incomes facing rising costs of living.
For full plan details, availability, and eligibility visit https://www.cloverhealth.com/plans.
“We are proud to reaffirm our commitment to New Jersey by maintaining our affordable benefit-rich PPO plans for 2025,” said Jamie Reynoso, Clover’s CEO of Medicare Advantage. “At a time when many plans are scaling back, Clover is the calm in the eye of the storm, delivering stability and increased value for our members.”
Clover’s 2025 plans in New Jersey focus on PPOs, but also include HMO offerings to cater to a wide range of healthcare needs. PPO plans offer highly competitive in-network and out-of-network costs, empowering members to access the care they need without the burden of high out-of-pocket expenses. For 2025, Clover has strengthened its product positioning to minimize disruption while delivering added value to members including low specialist and prescription drug copays, enhanced OTC and dental allowances, and a rewards program with the potential to earn up to $400 annually for completing healthy activities.
“After a decade of serving New Jersey’s Medicare beneficiaries, we understand the unique struggles they face, and we are committed to providing plans that deliver premium value as well as help them manage their day-to-day healthcare costs,” added Reynoso. “From offering the $400 rewards program to ensuring access to low-cost prescriptions and primary care, we’re here to help our members stay healthy without compromising on quality or affordability.”
Clover’s 2025 PPO plans received a 4 Star rating from the Centers for Medicare and Medicaid Services (“CMS”). Currently, over 95% of Clover’s Medicare Advantage membership is served through its PPO plans.
For information on Clover Health’s Medicare Advantage plans, visit www.cloverhealth.com.
Federal Contracting Disclaimer: Clover Health is a Preferred Provider Organization (PPO) and a Health Maintenance Organization (HMO) with a Medicare contract. Enrollment in Clover Health depends on contract renewal.
subslover
4 주 전
Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025
Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience
FRANKLIN, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare and Medicaid Services (“CMS”) has increased the Star rating of its PPO Medicare Advantage (“MA”) plans to 4 Stars for 2025, which will affect payment year 2026. Additionally, CMS increased the rating of Clover’s HMO MA plan to 3.5 Stars. Currently, over 95% of Clover’s Medicare Advantage membership is served through its PPO plans.
Each year CMS rates every plan on its healthcare quality and drug plan, and issues a Star rating on a scale of 1 to 5 Stars. For this measurement year, Clover’s overall Star rating was driven by the Company’s exceptional performance across a number of measures including Medication Adherence, the Healthcare Effectiveness Data and Information Set (“HEDIS”), and Consumer Assessment of Healthcare Providers and Systems (“CAHPS”). Clover earned an impressive 4.94 out of 5 Stars on HEDIS in particular, which is a set of performance measures quantifying a plan’s ability to deliver preventative screenings and comprehensively manage a range of health issues including diabetes, cancer, and heart disease.
"At Clover Health, our mission is centered around improving healthcare outcomes for our members, and our 4-Star CMS rating reaffirms our commitment to this goal,” said Andrew Toy, CEO of Clover Health. “Our investment in quality far exceeds industry standards, as demonstrated by our exceptional HEDIS score. By leveraging the power of Clover Assistant technology, we’re empowering physicians with real-time insights that directly enhance the quality of care through better preventive services and care coordination. We will continue prioritizing these efforts to drive impactful, long-term health improvements for our members."
"What we’ve been able to accomplish with this year’s Star ratings is a manifestation of the foundational improvements we’ve built over the last several years," said Jamie Reynoso, CEO of Medicare Advantage, Clover Health. "With a higher Star rating, we are able to further reinvest in more competitive benefits, which we believe will deliver greater value to our members while fueling continued membership growth. This milestone allows us to scale our impact to more people on Medicare without compromising our financial strength or commitment to care quality.”
To learn more about Clover Health and its Medicare Advantage plans visit www.cloverhealth.com. For providers, health systems and plans interested in learning about how they can use Clover’s proprietary technology stack to succeed in value based care, visit www.counterparthealth.com.
Federal Contracting Disclaimer: Clover Health is a Preferred Provider Organization (PPO) and a Health Maintenance Organization (HMO) with a Medicare contract. Enrollment in Clover Health depends on contract renewal.
subslover
4 주 전
Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer
Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health
FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart’s clinical strategy and product roadmap for Counterpart Assistant, the company’s proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”).
David Tsay is a distinguished physician executive with deep expertise and over two decades of experience in health technology, product development, and clinical innovation. Prior to Counterpart, Dr. Tsay served in clinical leadership roles in the technology industry, most recently as Chief Medical Officer at Cue Health where he led regulatory, clinical, and medical affairs. Before Cue Health, Dr. Tsay led the clinical team for digital health medical device products at Apple. Prior to Apple, Dr. Tsay served as Associate Chief Transformation Officer at New York-Presbyterian (NYP), one of the nation's most comprehensive academic healthcare delivery systems, leading digital transformation initiatives for NYP in artificial intelligence, automation, and digital web/mobile technologies.
Dr. Tsay received his BA in Computer Science and Physics from Columbia University College, M.D., Ph.D degrees from Columbia University College of Physicians and Surgeons, and is board certified in internal medicine and cardiology.
"Counterpart Health is built on groundbreaking technology that empowers physicians to excel in value-based care, particularly in the management of chronic diseases," said Conrad Wai, CEO of Counterpart Health. "Dr. Tsay’s world-class expertise in clinical innovation and health technology makes him a valuable addition to our team. I’m confident that his leadership will be instrumental as we accelerate our expansion into more value-based healthcare networks and systems nationwide."
"I’ve had the privilege of contributing to world-class institutions like Apple and NewYork-Presbyterian, which operate at the critical crossroads of healthcare and technology. Counterpart attracted me because it offers one of the most compelling solutions I’ve encountered," Tsay remarked. "With an increasing number of providers looking to deliver value-based care, Counterpart Assistant provides an innovative technology designed specifically for this purpose. I look forward to working alongside this skilled team in its mission to help improve providers’ and patients’ lives."
For companies interested in learning more about how Counterpart can reduce the total cost of care in value-based care models through advanced chronic disease management, visit www.counterparthealth.com.
About Counterpart Health
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform. Counterpart Health’s flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health’s Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Press Contact:
Andrew Still-Baxter
press@cloverhealth.com
Investor Relations Contact:
Jimmy Joe
1 월 전
Maybe the SEC should investigate TRADE SWAPS designed to suppress the share price of MANY tickers.
Who are the MMs suppressing this ticker. The usual suspects~? CDEL and Virtu~?
Just saying...............
They will not investigate their own, the 1%ers......... Instead they protect them, while they do not protect retail investors, institutions, and pensions that follow the rules. All in my OPINION~!
CLOV still naked shorted......... anyone who denies that is a liar. Again MY OPINION~!
They scalped this ticker 3 years ago and left it for dead, or hoping it would die. It did not die as they had hoped.
Also my opinion.
$CLOV baby~!
subslover
1 월 전
From last night's 8K. = By letter dated September 26, 2024 (the “Notice”), the Staff of the Securities and Exchange Commission's (the "SEC") Division of Enforcement notified Clover Health Investments, Corp. (the “Company”) that the SEC had concluded its investigation of the Company commenced in February 2021 (the "Investigation"), and based on the information that the SEC had as of the date of the Notice, the Staff did not intend to recommend an enforcement action by the SEC against the Company relating to the Investigation. The Notice was provided under the guidelines set forth in the final paragraph of Securities Act Release No. 5310.
The Investigation was previously disclosed by the Company in its periodic reports under the Securities Exchange Act of 1934, as amended. Additional information regarding the Investigation can be found in the Company’s prior filings, including the Company’s Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on August 8, 2024.
Hot Features
프리미엄
브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
MadeMillions$
2 주 전
PennyWorld
3 주 전
Monksdream
1 월 전
glenn1919
1 월 전
